Regeneron Pharmaceuticals' Operating Expenses rose 7.33% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 billion, marking a year-over-year increase of 6.95%. This contributed to the annual value of $10.2 billion for FY2024, which is 12.58% up from last year.
Regeneron Pharmaceuticals' Operating Expenses amounted to $2.7 billion in Q3 2025, which was up 5.06% from $2.6 billion recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Operating Expenses ranged from a high of $2.8 billion in Q4 2024 and a low of $1.4 billion during Q1 2021.
Moreover, its 3-year median value for Operating Expenses was $2.5 billion (2023), whereas its average is $2.5 billion.
Per our database at Business Quant, Regeneron Pharmaceuticals' Operating Expenses spiked by 84.09% in 2021 and then fell by 2.46% in 2022.
Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Operating Expenses stood at $2.3 billion in 2021, then decreased by 1.92% to $2.3 billion in 2022, then increased by 8.55% to $2.5 billion in 2023, then increased by 13.72% to $2.8 billion in 2024, then grew by 7.33% to $2.7 billion in 2025.
Its last three reported values are $2.7 billion in Q3 2025, $2.6 billion for Q2 2025, and $2.4 billion during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value